Revenue
2020
2021
2022
2023
2024
2025
ImageneBio, Inc. (IMA)
Price$4.86Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $800,000 | $3.5M | $9.2M | $15.6M | $31.0M | $9.2M |
| Research & development | $28.5M | $32.1M | $59.7M | $64.3M | $47.1M | $44.8M |
| Operating expenses | $49.3M | $40.5M | $84.6M | $86.5M | $65.1M | $53.7M |
| Operating income | −$48.5M | −$37.0M | −$75.4M | −$70.9M | −$34.1M | −$44.5M |
| Operating margin | −6,056.38% | −1,057.14% | −823.33% | −453.99% | −110.18% | −484.22% |
| EBITDA | −$48.1M | −$35.9M | −$74.4M | −$70.2M | −$33.6M | −$44.2M |
| EBITDA margin | −6,006.38% | −1,025.71% | −812.19% | −449.18% | −108.42% | −480.95% |
| Net income | −$45.3M | −$36.6M | −$68.2M | −$68.8M | −$34.1M | −$44.3M |
| Net profit margin | −5,668.63% | −1,044.80% | −744.17% | −440.29% | −110.10% | −481.36% |
| Basic EPSper basic share | -$9.64 | -$22.10 | -$1.63 | -$1.90 | -$1.22 | -$16.00 |
| Diluted EPSper diluted share | -$9.64 | -$22.10 | -$1.63 | -$1.90 | -$1.22 | -$16.00 |
Owners
Reported shareholders
≈9.89%of listed shares
Wang Jonathan Jian1.12M shares · Jul 25, 2025
View holders
| Holder | % owned |
|---|---|
Wang Jonathan Jian | ≈9.89%1.12M shares |
BVF INC/IL | 9.84%1.11M shares |
Blue Owl Capital Holdings LP | 8.14%917.69K shares |
ORBIMED ADVISORS LLC | 8.06%909.27K shares |
Cable Car Capital, LP | 6.93%781.6K shares |
Bonita David P | ≈6.86%773.75K shares |
Stampacchia Otello | —455.36K shares |
Omega Fund Management, LLC | 4.04%455.36K shares |
RTW INVESTMENTS, LP | 2.97%334.45K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.84%320.52K shares |
Trails Edge Capital Partners, LP | 2.50%282K shares |
Wang Stephen Hui | ≈2.22%250.72K shares |
BML Capital Management, LLC | 1.78%200.73K shares |
Monashee Investment Management LLC | 1.71%192.34K shares |
BlackRock, Inc. | 1.20%135.09K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.77%86.93K shares |
Yarema Kristin | ≈0.76%85.4K shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.59%66.67K shares |
Lally Robert B | ≈0.52%58.78K shares |
CITADEL ADVISORS LLC | 0.49%55.61K shares |
Percentages use 11.28M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 14, 2026Form 4 | Bonita David PDirector | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 384.7K | — | — | 384.7K |
| Apr 14, 2026Form 4 | Bonita David PDirector | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 336.6K | — | — | 336.6K |
| Apr 14, 2026Form 4 | OrbiMed Genesis GP LLC +2Director | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 384.7K | — | — | 384.7K |
| Apr 14, 2026Form 4 | OrbiMed Genesis GP LLC +2Director | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 336.6K | — | — | 336.6K |
| Dec 24, 2025Form 4 | SLATTERY JOSEPH PDirector | BuyCommon Stock | 16.0K | $5.99 | $95.8K | 16.0K |